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uscle damage has been shown to enhance the
contribution of bone marrow–derived cells
(BMDCs) to regenerating skeletal muscle. One
responsible cell type involved in this process is a hemato-
poietic stem cell derivative, the myelomonocytic precursor
(MMC). However, the molecular components responsible
for this injury-related response remain largely unknown.
In this paper, we show that delivery of insulin-like growth
factor I (IGF-I) to adult skeletal muscle by three different
methods—plasmid electroporation, injection of geneti-
M
 
cally  engineered myoblasts, and recombinant protein
injection—increases the integration of BMDCs up to
fourfold. To investigate the underlying mechanism, we
developed an in vitro fusion assay in which co-cultures of
MMCs and myotubes were exposed to IGF-I. The number
of fusion events was substantially augmented by IGF-I, in-
dependent of its effect on cell survival. These results pro-
vide novel evidence that a single factor, IGF-I, is sufﬁcient
to enhance the fusion of bone marrow derivatives with
adult skeletal muscle.
 
Introduction
 
There is now extensive documentation that bone marrow–derived
cells (BMDCs) can contribute to diverse nonhematopoietic tis-
sues such as skeletal muscle, liver, brain, and epithelia after a
bone marrow transplant (BMT) of genetically marked cells
(GFP
 
 
 
, LacZ
 
 
 
, or Y chromosome
 
 
 
; Ferrari et al., 1998; Bittner
et al., 1999; Gussoni et al., 1999; Lagasse et al., 2000; Mezey
et al., 2000; Krause et al., 2001; LaBarge and Blau, 2002; Bra-
zelton et al., 2003; Weimann et al., 2003; Brazelton and Blau,
2005). The physiological relevance of these events has been
called into question because of their relatively low frequency
(Wagers et al., 2002; Massengale et al., 2005). Nonetheless,
several published studies have demonstrated that the contribu-
tion of BMDCs to adult skeletal muscle is an inherent property
of these cells, which increases markedly in response to tissue
stress or injury. First, diverse muscles exhibit an intrinsic
1,000-fold difference (from 0.005 to 5.0%) in their ability to
incorporate BMDCs (Brazelton et al., 2003). Second, when
muscle damage is inflicted by toxin injection, muscle exercise,
or muscle overload, a substantial increase in skeletal muscle fi-
bers that incorporate BMDCs is observed (Fukada et al., 2002;
LaBarge and Blau, 2002; Camargo et al., 2003; Dreyfus et al.,
2004; Palermo et al., 2005). Third, in parabiosis experiments in
which two animals are surgically joined so that they share chi-
meric blood, BMDCs transit via the circulation to damaged
muscle and fuse with skeletal myofibers in the absence of BMT-
associated variables such as lethal irradiation and dysregulation
of cytokines (Sherwood et al., 2004a; Palermo et al., 2005).
BMDCs may contribute to muscle by diverse mecha-
nisms. We and others previously proposed that BMDCs en
route to muscle can follow a biological progression. Initially,
they give rise to cells with many properties typical of muscle-
specific stem cells (satellite cells) and then fuse to mature myo-
fibers under damage conditions, such as toxin-induced injury
or exercise on a running wheel (Fukada et al., 2002; LaBarge
and Blau, 2002; Dreyfus et al., 2004). Recently, another study
showed that BMDCs that incorporate into muscle after BMT
do not exhibit full myogenicity on par with endogenous cells;
however, the finding that they do not fuse with each other but
do fuse with muscle cells both in vitro and in vivo suggests that
they share several features with myogenic cells (Sherwood et
al., 2004b). It is quite possible that a proportion of BMDCs
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fuse directly with myofibers without passage through the satel-
lite cell compartment. Thus, these mechanisms of BMDC con-
tribution to skeletal muscle may coexist.
Several studies have addressed the nature of the BMDCs
capable of contributing to adult skeletal muscle. When the
blood was reconstituted after transplantation of a single he-
matopoietic stem cell (HSC), labeled myofibers containing
BMDCs were readily detected in skeletal muscle, showing that
these cells have the capacity to generate derivatives that fuse
with muscle (Camargo et al., 2003; Corbel et al., 2003). The
relevant HSC derivative that participates in muscle regenera-
tion has been identified as the same as that suggested for liver
(Willenbring et al., 2004), the myelomonocytic precursor
(MMC; Lin
 
 
 
ckit
 
 
 
Sca1
 
 
 
; Camargo et al., 2003; Doyonnas et
al., 2004; Ojima et al., 2004). After injection of notexin or car-
diotoxin into the muscle, incorporation of MMCs into regenerat-
ing muscle fibers was observed. Thus, myeloid HSC derivatives
have been shown to be a source of cells that can contribute to
muscle fibers.
To date, knowledge of the molecular mechanisms and
components responsible for BMDC contribution to muscle has
been lacking. An identification of soluble factors involved in
this “damage response” is of fundamental interest and is crucial
if we are to increase this relatively rare event in a therapeutic
context. One of the many potentially relevant soluble factors is
insulin-like growth factor I (IGF-I), a secreted growth factor
that regulates several diverse cellular pathways, including sur-
vival, proliferation, and differentiation (Stewart and Rotwein,
1996). Two major classes of IGF-I isoforms that result from al-
ternative splicing have been described previously (Goldspink
and Yang, 2004; Shavlakadze et al., 2005). IGF-I class 2 pro-
teins are primarily produced in the liver and secreted into the
circulation and are the major endocrine effectors of growth
hormone (Yakar et al., 1999). Accordingly, conditional knock-
out mice in which IGF-I expression was abrogated only in the
liver exhibited postnatal growth retardation, despite normal
levels of growth hormone (Sjogren et al., 2002). By contrast,
IGF-I class 1 isoforms are widely expressed in most tissues and
remain localized within the tissue in which they are expressed.
In adult skeletal muscle, two class 1 isoforms of IGF-I have
been identified, IGF-IEa and mechano growth factor (MGF;
Yang et al., 1996; McKoy et al., 1999), both of which are se-
creted but retained within muscle tissue (LeRoith and Roberts,
1991) and are up-regulated upon muscle damage (Hill and
Goldspink, 2003; Hill et al., 2003). MGF has been shown in
vitro to stimulate myoblast proliferation, but studies in vivo are
lacking (Yang and Goldspink, 2002). IGF-IEa induces muscle
hypertrophy, blocks muscle atrophy, and has been shown to be
critical to satellite cell activation and regeneration of skeletal
muscle (Sommerland et al., 1989; Barton-Davis et al., 1998;
Musaro et al., 2001; Hill and Goldspink, 2003; Stitt et al.,
2004; Schakman et al., 2005). IGF-I–null mice die immediately
after birth and exhibit multiple tissue defects, including signs
of skeletal muscle dystrophy (Liu et al., 1993; Powell-Braxton
et al., 1993). Mice transgenic for IGF-IEa under the control of a
muscle-specific promoter display marked muscle hypertrophy
after birth (Musaro et al., 2001). A recent study using mice
transgenic for IGF-IEa suggested that this factor could play a
role in the contribution of BMDCs to skeletal muscle (Musaro
et al., 2004) because after muscle damage an increased inci-
dence of bone marrow–derived ckit
 
 
 
 cells present in skeletal
muscle was observed relative to wild-type mice. However, in-
terpretation of these experiments is complicated by the facts
that IGF-I was present from conception onward and that multi-
ple other damage-associated factors were up-regulated by ex-
tensive tissue injury.
In this paper, we investigated whether in the presence of
mild damage, IGF-I alone could enhance the contribution of
BMDCs to mature muscle fibers of adult wild-type mice. Three
modes of IGF-I delivery yielded similar results, showing that
the effects were not the result of the experimental paradigm
used. IGF-I increased the number of GFP
 
 
 
 myofibers in wild-
type mice that had received a BMT from GFP
 
 
 
 transgenic do-
nors up to fourfold relative to untreated controls. To understand
the underlying mechanism of IGF-I action, hematopoietic sub-
fractions were co-cultured with differentiating myotubes in the
presence or absence of IGF-I. We observed an increase in fu-
sion between MMCs and myotubes that could be dissociated
from the well-documented effect of IGF-I in increasing cell
survival (Minshall et al., 1997; Burgess et al., 2003). Fusion
was dependent on the culture media and stage of differentiation
of the cells. These results are novel in that they demonstrate
that a single factor, IGF-I, is sufficient to promote the forma-
tion of heterokaryons between myelomonocytic BMDC deriv-
atives and differentiated muscle cells and can enhance their
contribution to adult skeletal muscle in vivo.
 
Results
 
DNA electrotransfer of IGF-I increases 
contribution of BMDCs to adult skeletal 
muscle
 
Electrotransfer of DNA has been shown to be an efficient strat-
egy for introducing genes into skeletal myofibers (Mir et al.,
1999; Vilquin et al., 2001; Gollins et al., 2003; Schakman et
al., 2005). The exposure of tissues to electric pulses produces a
transient and reversible permeabilization of cell membranes,
allowing DNA to enter target cells. The efficiency of uptake of
electroporated naked DNA has been reported to be as high as
40% (Bertrand et al., 2003; Dona et al., 2003) of total myofi-
bers, considerably higher than the 1% uptake reported for in-
jected naked DNA (Wolff et al., 1990).
The two muscle-specific IGF-I isoforms IGF-IEa and
MGF were selected for study. Both isoforms were previously
reported to be up-regulated upon muscle damage (Hill and
Goldspink, 2003). To confirm that this was the case, mouse
skeletal muscle tissues were injected with notexin, a potent in-
ducer of muscle damage (Harris et al., 1974; Pluskal et al.,
1978; Klein-Ogus and Harris, 1983). RT-PCR analysis of total
RNA from muscle revealed an increase in IGF-IEa and MGF
transcripts 8 d after injury (Fig. 1 a).
To determine whether IGF-IEa or MGF could substitute
for extensive muscle damage as a signal to enhance BMDC
contribution to muscle, they were each delivered to skeletal 
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muscle by DNA electrotransfer. cDNAs encoding the two iso-
forms were obtained by RT-PCR of total RNA from damaged
muscle and cloned into the pVIVO vector (see Materials and
methods). The expression of IGF-I was linked to that of CD8
by an internal ribosome entry site sequence (IGF-IEa.CD8 and
MGF.CD8), so that IGF-I–expressing electroporated myofibers
could be identified by expression of CD8 on their membranes.
Tibialis anterior (TA) muscles of GFP-BMT wild-type
mice 8 wk after transplantation were electroporated with plas-
mids encoding one of the two isoforms of IGF-I and CD8, or
only CD8. Muscles were harvested from five mice in each of
the three groups 4 wk later and analyzed for the presence of
GFP
 
 
 
 myofibers (Fig. 1, b and c). Myofibers that were trans-
duced by electrotransfer were identified by the expression of
CD8 on their membranes (Fig. 1 c, left). Coincident immuno-
fluorescent staining for CD8 and GFP allowed a determination
of the frequency of myofibers that had incorporated BMDCs
from the circulation (GFP
 
 
 
) relative to those expressing the
IGF-I isoforms (CD8
 
 
 
; Fig. 1 c, right, arrows). GFP
 
 
 
 intersti-
tial cells (
 
 
 
10 
 
 
 
m) visible in muscle transverse sections are
donor-derived blood cells. The expression of IGF-I isoforms by
myofibers led to a marked increase in the contribution of cells
from the circulation, as demonstrated by the increase in GFP
 
 
 
myofibers among the total CD8
 
 
 
 myofibers, relative to controls
(P 
 
  
 
0.02; Fig. 1 b).
The effects of IGF-I supersede the effects of damage
because of the mode of delivery. Electroporation appeared to
result in mild damage, as the frequency of BMDC incorpora-
tion observed in the control (CD8 only; Fig. 1 b) was somewhat
greater than that which we typically observed in undamaged
muscle (
 
 
 
0.05%; LaBarge and Blau, 2002; Brazelton et al.,
2003). To establish the extent of damage, the percentage of
centrally nucleated myofibers (a standard method to measure
skeletal muscle injury) was assessed and determined to be
5.4 
 
 
 
 0.3% in the three experimental groups tested (control,
Igf-IEa, and MGF). By contrast, muscles damaged by injection
of notexin, a standard means of experimentally inducing tissue
damage, exhibited 73.4 
 
 
 
 8.2% centrally nucleated myofibers.
Thus, the damage caused by electroporation is relatively mild.
To ensure that the increase in contribution of BMDCs to skele-
tal muscle was not attributable to the mode of IGF-I delivery
but rather to the growth factor itself, two other modes of deliv-
ery were tested.
 
Myoblast-mediated IGF-I delivery 
increases contribution of BMDCs to 
adult skeletal muscle
 
Genetically engineered myoblasts provide a potent means for
delivering proteins to skeletal muscle tissues. After injection
into adult skeletal muscle, these cells fuse with the preexisting
muscle fibers of the host. Myoblast-mediated gene delivery to
skeletal or heart muscle was first shown to lead to physiological
levels of secreted proteins in the circulation (e.g., human
growth hormone; Barr and Leiden, 1991; Dhawan et al., 1991).
Subsequently, localized secretion of proteins such as VEGF-A
within heart and skeletal muscle tissues has been achieved by
myoblast-mediated delivery, leading to novel insights into its
mechanism of action in angiogenesis (Springer et al., 1998;
Lee et al., 2000; Ozawa et al., 2004). Primary myoblasts previ-
ously engineered to express 
 
 
 
-galactosidase (
 
 
 
-gal; Rando and
Blau, 1994) were transduced with a retroviral vector encoding
IGF-IEa.CD8, MGF.CD8, or an empty control vector (CD8
cassette only; Springer and Blau, 1997; Springer et al., 1998).
All transduced cells were isolated by flow cytometry (FACS)
using an antibody to CD8. IGF-I expression in these myoblast
populations was confirmed by Western blot (Fig. 2 a).
Wild-type mice that had been lethally irradiated and had
their blood reconstituted by transplantation of GFP-expressing
whole bone marrow were injected 8 wk later in the TA muscles
with 5 
 
  
 
10
 
5
 
 myoblasts. These myoblasts expressed one of the
two isoforms of IGF-I as well as CD8 or only CD8 (control).
Muscles were harvested 4 wk later from five mice in each of the
Figure 1. DNA electrotransfer of IGF-I increases the contribution of BMDCs
to skeletal muscle. (a) The two muscle-specific isoforms, IGF-IEa and MGF,
are shown to be up-regulated in the muscle after notexin damage as
shown by RT-PCR analysis. (b) Plasmids encoding IGF-IEa.CD8,
MGF.CD8, or CD8 only (control) were electroporated into the TA muscles
of mice that had received a BMT 8 wk earlier, and muscles were har-
vested 4 wk after DNA delivery. The percentage of GFP
 CD8
  myofibers
relative to total CD8
  myofibers is shown (  SEM). P value was deter-
mined with a t test. *, P   0.02. (c) Immunofluorescence images of trans-
verse sections of muscle stained for CD8 only (left) or for GFP and CD8
(right). GFP
  cells  10  m are blood cells. Arrows indicate examples of
CD8
  myofibers that were also GFP
 . Bars, 50  m. 
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three groups and analyzed for the presence of GFP
 
 
 
 myofibers
(Fig. 2, b and c). 
 
 
 
-gal expression indicates those myofibers that
incorporated myoblasts expressing IGF-IEa, MGF, or CD8 only,
whereas GFP expression indicates those myofibers that incorpo-
rated BMDCs from the circulation. Consistent with the results
obtained by electrotransfer, the expression of IGF-I isoforms by
myofibers led to a marked increase in the contribution of cells
from the circulation as demonstrated by the increase in GFP
 
 
 
myofibers among the total 
 
 
 
-gal
 
 
 
 myofibers (P 
 
  
 
0.02; Fig. 2 b).
These results suggest that IGF-I, which is up-regulated together
with many other factors in the course of muscle damage, can
elicit a similar response on its own. In the myoblast-mediated de-
livery paradigm the muscle damage assessed as the percentage of
centrally nucleated myofibers was 1.1 
 
 
 
 0.4%. For comparison
and to rule out the possibility that this effect was the result of
myoblast injection and a consequent increase in the fusogenic
environment, a third mode of IGF-I delivery was tested.
 
Injection of recombinant IGF-I protein 
increases the contribution of BMDCs to 
adult skeletal muscle
 
To prove definitively that IGF-I protein increases the contri-
bution of BMDCs to muscle, the recombinant IGF-I protein
was delivered by intramuscular injection. The commercially
available recombinant protein is a purified peptide of 70
amino acids corresponding to exons 3 and 4 of the IGF-I gene,
which constitutes the mature processed peptide with domains
B, C, A, and D (Bell et al., 1986; Shimatsu and Rotwein,
1987). This delivery system is substantially different from the
two methods described in Figs. 1 and 2 because it is transient.
Different amounts of IGF-I (1, 5, and 10 
 
 
 
g) were injected
into the TA muscles of wild-type mice that had received a
BMT with GFP-labeled bone marrow 8 wk earlier, and the
muscles of three mice in each group were analyzed 4 wk later.
A dose-dependent increase in the number of total GFP
 
 
 
 myo-
fibers per transverse section was observed in IGF-I–injected
relative to the saline-injected muscles (P 
 
  
 
0.01; Fig. 3). By
contrast, injection of a cytokine, IL-4, recently reported to
play a role in the fusion of myoblasts with myocytes to form
multinucleated myotubes (Horsley et al., 2003), did not in-
crease the frequency of GFP
 
 
 
 myofibers (unpublished data).
The extent of muscle damage assessed as the percentage of
centrally nucleated myofibers was 3.3 
 
 
 
 0.8%, using this
mode of IGF-I delivery.
Figure 2. Myoblast-mediated delivery of IGF-I increases the contribution
of BMDCs to skeletal muscle. (a) Western blot analysis of IGF-I expression
by retrovirally transduced myoblasts isolated based on CD8 expression us-
ing FACS. IGF-IEa migrates as a 14-kD protein and MGF as a 12-kD pro-
tein. (b) 5  10
5 myoblasts were injected into the TA muscles of mice that
had received a BMT 8 wk earlier, and muscles were harvested 4 wk after
cell injection. The percentage of GFP
  -gal
  myofibers relative to total
 -gal
  myofibers is shown (  SEM). P value was determined with a t test.
*, P   0.02. (c) Muscle sections were analyzed for  -gal expression (top),
and serial sections were analyzed by immunofluorescence staining for
GFP and laminin (bottom). Arrows indicate examples of  -gal
  myofibers
that were also GFP
 . Bars, 15  m. Figure 3. Recombinant IGF-I protein injection increases the contribution
of BMDCs to skeletal muscle. (a) Saline (control) or recombinant IGF-I pro-
tein (1, 5, and 10  g) was injected into the TA muscles of mice that had
received a BMT 8 wk earlier, and muscles were harvested 4 wk after
protein injection. Immunofluorescence images of transverse sections of
muscles injected with saline or 5  g IGF-I and stained for laminin only
(top) or for GFP and laminin (bottom) are shown. Arrows indicate GFP
 
myofibers. (b) The total numbers of GFP
  myofibers per transverse section
are shown (  SEM). Asterisk indicates values that were significantly dif-
ferent from the control (P   0.05). P value was determined with a t test.
Significance of the values from the dose–response trendline was calculated
by using the Pearson correlation coefficient (P   0.01). Bars, 50  m. 
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Because all three modes of IGF-I delivery resulted in a
substantial fourfold increase in BMDC contribution to adult
skeletal muscle, these effects can be attributed to IGF-I, not the
delivery system used. The damage induced in all cases was mi-
nor (1–5% centrally nucleated myofibers). Yet, the frequency
of GFP
 
 
 
 myofibers observed with all three modes of IGF-I de-
livery was similar to that previously reported after notexin tis-
sue injury (
 
 
 
75% centrally nucleated myofibers; LaBarge and
Blau, 2002; Palermo et al., 2005), suggesting that IGF-I leads
to a contribution of BMDCs to muscle on par with extensive
muscle damage.
 
MMCs fuse spontaneously with 
differentiated myotubes in vitro
 
To elucidate the mechanism underlying the IGF-I–enhanced
BMDC contribution to skeletal muscle in vivo, BMDCs were
co-cultured with myogenic cells in vitro. Because we and oth-
ers previously showed that the bone marrow derivatives of
HSCs capable of fusing with myofibers in vivo are the MMCs
(Camargo et al., 2003; Doyonnas et al., 2004; Ojima et al.,
2004), experiments were designed to assess whether MMCs in
co-culture with muscle cells were able to fuse with myotubes.
Various experimental conditions were tested (Fig. 4 a). When
freshly isolated MMCs were immediately co-cultured with
myoblasts in low-serum myoblast differentiation medium (DM),
fusion events were never observed, even after 6 d (Fig. 4 a, 1).
By contrast, when MMCs were pretreated with high-serum
myoblast growth medium (GM), fusion was observed. For in-
stance, when MMCs and myoblasts were each cultured in GM
for 3 d and then co-cultured in DM, GFP
 
 
 
 myotubes containing
myogenin-expressing nuclei were detected as early as 4 d (Fig.
4, a [2] and b–b”). Notably, when MMCs were cultured in GM
for 3 d and then plated together with 3-d-old myotubes in DM,
GFP
 
 
 
 myotubes containing myogenin-expressing nuclei were
visible as early as 12 h after co-culture (Fig. 4 a, 3), and 
 
 
 
90%
of GFP
 
 
 
 myotubes contained three or more nuclei (not de-
picted). Together, these results suggest that exposure to GM is
a prerequisite for MMCs to fuse. In addition, these “activated”
MMCs can fuse with well-differentiated multinucleated myo-
tubes. In none of these conditions in eight independent experi-
ments were unfused GFP
 
 
 
 mononucleated bone marrow cells
that expressed myogenin ever detected (Fig. 4, b–b”, arrow-
heads). The frequency of these fusion events is low (
 
 
 
0.013%)
but comparable with that previously reported by others for ad-
herent bone marrow mesenchymal cells that are stromal deriva-
tives (Shi et al., 2004; Lee et al., 2005). Thus, nonadherent
HSC derivatives are as capable of fusing with muscle as adher-
ent mesenchymal cells.
To determine definitively that fusion was the basis for the
appearance of GFP
 
 
 
 myotubes rather than transdifferentiation
of MMCs to myogenic cells tested under our culture condi-
tions, an additional set of experiments was performed. MMCs
were isolated from a Cre-reporter mouse (R26R; Soriano,
1999), stimulated by GM for 3 d, and co-cultured with Cre-
expressing myoblasts in DM for 4 d (Fig. 4 a, 2). After fusion
between MMCs and myotubes, DNA recombination mediated
by the Cre recombinase resulted in 
 
 
 
-gal expression, as shown
in Fig. 4 c. This experiment provides conclusive evidence that
hematopoietic MMCs can fuse with muscle cells.
Moreover, to determine whether MMCs fuse with either
mononucleated myoblasts or with differentiated multinucle-
ated myotubes, we performed time-lapse confocal microscopy.
Myotubes were exposed to Ara-C to eliminate contaminating
proliferating myoblasts and co-cultured with MMCs (Fig. 4 a, 3).
In Fig. 5 (top eight panels), two muscle cells (arrows) are
shown fusing together to form a multinucleated myotube. Sub-
sequently, a GFP
 
 
 
 MMC (Fig. 5, arrowhead) fuses with the
multinucleated myotube only 5 h after the onset of co-culture
(bottom six panels). The entire time-lapse film of this micro-
scopic field is provided with a single channel of phase contrast
and GFP and the merged images (Video 1, available at http://
www.jcb.org/cgi/content/full/jcb.200506123/DC1). Using time-
lapse microscopy in two independent experiments, we detected
Figure 4. MMCs can fuse spontaneously in vitro with differentiated
myotubes. (a) Schematic of the co-culture experiments. (b and c) MMCs
were isolated by FACS from fresh bone marrow from GFP transgenic
mice, maintained in myoblast GM for 3 d, and co-cultured with wild-type
primary myoblasts and differentiation induced (DM) for 4 d, according to
scheme a (2). Phase-contrast (b) and laser-scanning confocal images of im-
munofluorescence for myogenin only (b’) or for GFP and myogenin (b”)
are shown. Arrows indicate an example of GFP
 myogenin
  multinucle-
ated myotube. Arrowheads indicate GFP
  MMCs that do not express myo-
genin. (c) MMCs were isolated by FACS from fresh bone marrow from
R26R Cre-reporter transgenic mice and co-cultured with Cre-expressing
myoblasts, according to scheme a (2). A  -gal
  multinucleated myotube
provides evidence of fusion between MMCs and Cre myotubes. 
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12 fusion events, 11 of which occurred with multinucleated
myotubes and only 1 with a myoblast. Together, these data
demonstrate that bone marrow MMCs can fuse in vitro with
multinucleated differentiated myotubes.
 
IGF-I promotes survival of MMCs in vitro
 
To test the potential role of IGF-I on the fusion of MMCs with
myotubes, we had to distinguish its effects on fusion from
those on survival. Accordingly, experiments were first de-
signed to determine whether IGF-I affects the survival and
proliferation of MMCs. Freshly isolated MMCs were isolated
from GFP
 
 
 
 bone marrow by FACS. MMCs were cultured
for 3 d in GM with or without IGF-I (100 ng/ml). Cells were
then harvested and counted, and cell cycle analysis was per-
formed using propidium iodide and FACS. As shown in Fig. 6,
IGF-I led to an increase in the number of cells within this
Lin
 
 
 
ckit
 
 
 
Sca1
 
 
 
 bone marrow fraction (P 
 
  
 
0.02). By contrast,
IGF-I did not lead to a change in the number of Lin
 
 
 
 cells (un-
published data). This potent effect on cell number resulted
from an increase in cell survival because no effect of IGF-I on
proliferation was observed, as indicated by the cell cycle profile,
which was not altered relative to untreated controls. Indeed,
14% of the cells were in S–G2/M phase in each case (Fig. 6 b).
As a control, when MMCs were cultured in bone marrow me-
dium in the presence of cytokines (IL3, IL6, and stem cell
factor), a medium in which they were highly stimulated to
proliferate, 35% of the cells were found in the S–G2/M phase
of the cell cycle (Fig. 6 b). Thus, IGF-I increased survival but
not proliferation of MMCs under the experimental conditions
used here.
 
IGF-I increases fusion of MMCs with 
differentiated myotubes independent of 
the IGF-I–mediated increase in cell survival
 
Experiments were designed to test the effect of IGF-I on the
fusion of MMCs with myotubes. A dose–response curve for
IGF-I effect on fusion was performed (50, 100, 200, and 400
ng/ml; unpublished data), and 100 ng/ml was the optimal IGF-I
Figure 5. MMCs fuse with differentiated multinucleated myotubes. MMCs
were isolated by FACS from fresh bone marrow from GFP transgenic mice,
maintained in myoblast GM for 3 d, and co-cultured with Ara-C–treated 3-d-
old primary wild-type myotubes, according to Fig. 4 a (3). Immediately after
the beginning of the co-culture, we started monitoring the cells using time-
lapse confocal microcopy. Arrows indicate muscle cells, and arrowheads in-
dicate MMCs (GFP
 ) that fuse with each other. The entire time-lapse film of
this microscopic field is provided with a single channel of phase contrast
and GFP and the merged images (Video 1, available at http://
www.jcb.org/cgi/content/full/jcb.200506123/DC1).
Figure 6. IGF-I promotes survival of MMCs. (a) MMCs were obtained by
FACS from freshly isolated bone marrow and 6   10
4 cells plated in myo-
blast GM for 3 d, with or without 100 ng/ml IGF-I. Cell counts were per-
formed on days 0 and 3. Final cell numbers are expressed as a percentage
of the initial number of cells plated on day 0 (  SEM). P value was deter-
mined with a t test. *, P   0.02. (b) Cell cycle profile using propidium
iodide for analysis of DNA content in MMCs with or without IGF-I after 3 d
of culture in the media indicated. Percentages of the cells in each specific
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concentration used for further experiments. GFP
  MMCs that
had been exposed in culture to myoblast GM for 3 d were co-
cultured with 3-d-old myotubes that had been exposed to the
DNA synthesis inhibitor Ara-C for 3 d to eliminate proliferat-
ing myoblasts. Co-cultures were maintained for the subse-
quent 4 d in the presence or absence of IGF-I (Fig. 7 a). As
shown in Fig. 7 a, we observed a twofold increase in the num-
ber of GFP
  myotubes containing myogenin-expressing nuclei
when IGF-I was added to co-cultures (95% confidence inter-
val based on the Poisson distribution). Under these conditions,
as shown in Fig. 5, GFP
  myotubes were visible as early as 5 h
after co-culture and increased for a period of 4 d thereafter.
This effect was not attributable to an increased survival of
these cells during co-culture because the number of MMCs
does not change in the presence or absence of IGF-I in DM
conditioned by myotubes (P   0.5; Fig. 7 b). An example of a
multinucleated GFP
  myotube with all nuclei positive for
myogenin is shown in Fig. 7 c. We conclude that IGF-I pro-
motes fusion of MMCs with mature myotubes and that this ef-
fect is not attributable to an increase in cell survival under the
experimental conditions used.
Discussion
Although HSC derivatives, specifically MMCs, have been
shown to incorporate into skeletal muscle after damage, the re-
sponsible damage-related molecules have yet to be identified.
In this paper, we show that administration to adult muscle of a
single growth factor, IGF-I, known to be up-regulated during
muscle regeneration substantially increases the contribution of
BMDCs to skeletal muscle in vivo in the presence of mild
damage. To date, tissue injury caused by myotoxins, sustained
exercise, or muscle overload was the only means reported for
triggering this response. Although injury is inherent in any de-
livery method, the extent of damage assessed as the percentage
of centrally nucleated myofibers in the three delivery systems
used in this study (DNA electrotransfer, myoblast-mediated
gene transfer, and recombinant protein injection) ranged from
1 to 5%. Myoblast-mediated gene transfer was the least inva-
sive means of delivery, considerably lower than that obtained
when muscles are damaged by notexin ( 75%). Thus, the ex-
perimental paradigms used in this study introduced only mild
injury to the tissue, and delivery of IGF-I enhanced the contri-
bution of BMDCs to skeletal muscle to the extent that it was on
par with notexin damage. The three different delivery methods
used show that the effect is specific to IGF-I and not related to
a given experimental strategy. Both DNA electrotransfer and
genetically engineered myoblasts result in constitutive delivery
of IGF-I over time, whereas recombinant protein injection re-
sults in a transient exposure of the tissue to IGF-I. These data
provide evidence that IGF-I alone can lead to increased incor-
poration of BMDCs into muscle fibers in vivo. Moreover, the
results are novel in that they show that delivery of a single fac-
tor increases BMDC contribution to muscle.
IGF-I has been implicated in the fusion of myoblasts with
myotubes in tissue culture (Jacquemin et al., 2004). IGF-I has
also been shown in transgenic animals to increase the recruit-
ment of BMDCs to damaged muscles (Musaro et al., 2004).
However, the fusion of myotubes with bone marrow cell types
has not previously been described, except for adherent mesen-
chymal stem cells derived from the stroma (Shi et al., 2004;
Lee et al., 2005). Our data demonstrate that fusion of MMCs
with myotubes occurs spontaneously in culture and is also en-
hanced when IGF-I is present. This is in contrast to a previous
study suggesting that HSCs and their derivatives were not able
to fuse with myotubes in vitro (Shi et al., 2004). In this paper,
we show the formation of heterokaryons between myotubes
and MMCs using two different experimental paradigms: (1)
GFP
  MMCs in co-culture with wild-type myotubes and
time-lapse microscopy and (2) R26R Cre-reporter MMCs in
co-culture with Cre-expressing myotubes, which results in
DNA recombination and expression of  -gal.
The failure to observe fusion of hematopoietic with myo-
genic cells by others was likely the result of the time period an-
alyzed, the differentiated state of the cells used (myoblasts),
and the absence of growth factor stimulation of hematopoietic
cells. In our studies, fusion of MMCs with myotubes occurred
within 5 h. Notably, fusion was not seen unless mature myo-
tubes were present and MMCs had been exposed to high-serum
medium before co-culture. Thus, the mechanisms that mediate
stromal mesenchymal cell fusion with mononucleated myo-
blasts may well differ from those that mediate MMC fusion
with multinucleate-differentiated myotubes.
These results also show that MMCs contribute to skeletal
muscle through a direct fusion mechanism and that they do not
get converted to myogenic precursors, as muscle-specific gene
Figure 7. IGF-I promotes fusion of MMCs
with myotubes. (a) MMCs were isolated by
FACS from fresh bone marrow from GFP trans-
genic mice, maintained in myoblast GM for
3 d, and co-cultured with 3-d-old primary wild-
type myotubes, in the presence or absence
of 100 ng/ml IGF-I, according to Fig. 4 a
(3). Asterisk indicates total numbers of
GFP
 myogenin
  multinucleated myotubes ob-
served after 4 d, shown with a 95% confidence
interval based on the Poisson distribution. (b)
For analyses of cell survival, MMCs were iso-
lated and immediately cultured in myotube-
conditioned DM in the presence or absence of 100 ng/ml IGF-I. Cell counts were performed on days 0 and 3. Final cell numbers are expressed as
percentages of the initial number of cells plated on day 0 (  SEM). P value was determined with a t test. P   0.5. (c) Laser-scanning confocal image of an
example of GFP
 myogenin
  multinucleated myotube; immunofluorescence shows nuclear muscle myogenin (red) and MMCs GFP (green).JCB • VOLUME 171 • NUMBER 3 • 2005 490
expression in MMCs in culture was never detected (unpub-
lished data). Cell survival of MMCs could be increased by
IGF-I in our studies, in agreement with those of others. How-
ever, we show that the increased fusion observed in the pres-
ence of IGF-I occurred in the presence of low-serum medium, a
condition under which IGF-I had no effect on cell survival.
Cell survival increased only when the cells were cultured in
GM and not in myotube-conditioned DM, the medium in which
fusion was observed.
The in vitro fusion assay described in this paper will allow
further characterization of the molecular components involved
in the spontaneous formation of heterokaryons in vivo. Several
studies performed in Drosophila melanogaster identified proteins
involved in the fusion of founder cells and fusion-competent cells
during muscle development (Chen and Olson, 2004, 2005).
The potential role of these proteins in the fusion of MMCs with
myotubes can now be tested. Such experiments will determine
whether muscle–muscle homofusion and muscle–MMC hetero-
fusion share similar components.
Materials and methods
Mice and BMT procedure
C57BL/6 wild-type and Cre-reporter R26R (Soriano, 1999) transgenic
mice were purchased from The Jackson Laboratory. C57BL/6-GFP trans-
genic mice (Wright et al., 2001) were a gift from I.L. Weissman (Stanford
University, Stanford, CA). For BMT, bone marrow from femurs and tibia of
GFP transgenic mice was harvested and cell suspensions were produced.
10
7 cells were transplanted by tail-vein injection into lethally irradiated
8-wk-old mice. All protocols were approved by the Administrative Panel
on Laboratory Animal Care at the Stanford University School of Medicine.
Electrotransfer of DNA into skeletal muscle
IGF-IEa and MGF cDNAs were obtained by RT-PCR from total RNA ob-
tained from damaged mouse skeletal muscles (forward primer for IGF-IEa
and MGF, caccatggggaaaatcagc; reverse primer for IGF-IEa, ctacattctg-
taggtcttgtt; reverse primer for MGF, ctacttgtgttcttcaaatgta). The PCR am-
plification of these two products was performed using an annealing tem-
perature of 56 C for 30 cycles.  -Actin control primers were as follows:
forward, ccgagcgtggctacagcttcac; reverse, gcacttgcggtgcacgatggag. The
PCR amplification of  -actin was performed using an annealing tempera-
ture of 64 C for 21 cycles. IGF-I cDNAs were cloned into the pVIVO vec-
tor (InvivoGen). Mice that had been GFP–bone marrow transplanted 8 wk
earlier were anesthetized with inhaled methoxyfluorane, the skin over their
TA muscle was shaved, their leg thickness was measured with a caliber,
and 10  g of plasmid (pVIVO, pVIVO–IGF-IEa, or pVIVO–MGF) in 30  l
of saline was injected (using an insulin syringe, 29-gauge needle) into
their TA muscles. Immediately after injection, an electric field was applied
to the TA with the Electro Square Porator ECM 830 (BTX; Genetronics)
using the following conditions: 200 V/cm, 20-ms pulse field, 176 ms of
interval, and eight serial pulses, according to the protocol from the
Rhone-Poulenc Company. Muscles were harvested 4 wk after injection
and processed as described in Tissue analysis.
Construction of IGF-IEa and MGF retroviral vectors and genetic 
engineering of primary mouse myoblasts
The IGF-IEa and MGF cDNAs were cloned into the MFG-retroviral vector
using the BamHI and XhoI sites, upstream of the internal ribosome entry
site–CD8 sequence (Springer et al., 1998). Primary myoblasts isolated
from C57Bl/6 mice and previously transduced to express  -gal from a
retroviral promoter (Rando and Blau, 1994) were infected again with
four successive rounds of MFG–IGF-IEa.CD8, MFG–MGF.CD8, or MFG-
CD8 control, yielding to  70% of the myoblasts of each population that
was CD8
 . Myoblast populations expressing CD8 on their membranes
were isolated using a FACStar cell sorter (Becton Dickinson), using 0.2
 g/ml of an anti–CD8-allophycocyanin–conjugated antibody (BD Bio-
sciences). 5   10
5 myoblasts from each population were injected in a
10- l volume using an insulin syringe (29-gauge needle) into the TA of
mice 8 wk after BMT.
For generating Cre-expressing myoblasts, primary myoblasts were
infected with a retrovirus carrying the Cre-recombinase gene together
with neomycin selection. Cells were subsequently selected with neomycin
(1 mg/ml), and these cells were used for the co-culture experiment.
Western blot
Western blot analysis for IGF-I was performed using 4  g/ml of a goat anti–
IGF-I primary antibody (Chemicon) and an anti–goat-HRP–conjugated sec-
ondary antibody (1:1,000 dilution; Bio-Rad Laboratories). For tubulin, 2
 g/ml antitubulin antibody (Sigma-Aldrich) and anti–mouse-HRP–conjugated
secondary antibody (1:10,000 dilution; Zymed Laboratories) were used.
Injection of recombinant mouse IGF-I
Mice that had been transplanted with GFP-expressing bone marrow 8 wk
earlier were anesthetized with inhaled methoxyflurane, were shaved over
their TA muscles, and received a single 10- l dose of 1, 5, or 10  g of
the recombinant mouse IGF-I (carrier free; R&D Systems) in saline by i.m.
injection into the TA muscle. As a control, saline alone was injected into
the contralateral leg. Muscles were harvested 4 wk after injection and pro-
cessed as described in Tissue analysis.
Tissue analysis
4 wk after injection, TA muscles were dissected and immersed in PBS/0.5%
EM-grade PFA (Polysciences) for 2 h at RT followed by overnight immersion
in PBS with 20% sucrose at 4 C. Fixed tissue was embedded in optimal cut-
ting temperature compound (Tissue-Tek; Sakura Finetek), snap-frozen in
isobutane and liquid nitrogen, and sectioned at 10  m thickness. Tissue
sections were blocked in PBS/20% normal goat serum/0.3% Triton X-100
(blocking buffer); incubated with primary antibodies (diluted in blocking
buffer; 2  g/ml rabbit anti-GFP [Invitrogen], 3  g/ml rat anti-laminin-2
[Upstate Biotechnology], or 5  g/ml rat anti-CD8a [BD Biosciences]); and
incubated with 10  g/ml of the secondary conjugated antibodies anti–
rabbit-Alexa488 and anti–rat-Alexa546 (Invitrogen). Sections were then
washed overnight and mounted with Fluoromount G. Images of muscle
transverse sections were acquired using an epifluorescent microscope
(Axioplan2; Carl Zeiss MicroImaging, Inc.), Fluar 20 /0.75 objective
lenses, and a digital camera (ORCA-ER C4742-95; Hamamatsu Photonics).
The software used for acquisition was OpenLab 4.0.2 (Improvision). All im-
ages were composed and edited in Photoshop 7.0 (Adobe). Background
was reduced using brightness and contrast adjustments, and color balance
was performed to enhance colors. All the modifications were applied to the
whole image using Photoshop 7.0 (Adobe). GFP
  muscle fibers were
counted using an epifluorescent microscope with a double-bandpass filter
that distinguishes between GFP and autofluorescence to ensure that the GFP
signal was authentic (Brazelton and Blau, 2005).
Quantification of GFP
  myofibers
To quantitate myofibers, we cut TA muscles, taking sections every 100  m.
All the sections were stained and analyzed, and GFP
  myofibers were
counted and expressed as the mean   SEM. In Figs. 1 and 2, all CD8
 
myofibers were counted, ranging from 60 to 500 CD8
  myofibers per
cross section. Among them, the percentage of GFP
  myofibers was calcu-
lated. In Fig. 3, total GFP
  myofibers per TA were scored (TA muscle con-
tains  2,000 myofibers per cross section).
Cell sorting by flow cytometry
Bone marrow from GFP mice was isolated, suspended in FACS buffer
(2.5% normal goat serum and 1 mM EDTA in PBS), and stained with 4
 g/ml specific antibodies to ckit and Sca1 directly conjugated to phyco-
erythrin, allophycocyanin, or phycoerythrin-Cy7 (all from BD Biosciences)
and a lineage panel (mixture of biotinylated antibodies to Ter119, B220,
CD3, Gr1, and CD11b; 1:30 dilution; BD Biosciences). Antibody-labeled
cells were separated using streptavidin coupled to magnetic beads (Mil-
tenyi Biotec) and then counterstained using 10  g/ml streptavidin Texas
red (BD Biosciences). Lin
 ckit
 Sca1
  cells (MMCs) were then fractionated
and collected by flow cytometry (DIVA-Van; Becton Dickinson). The purity
of the sorted MMC fraction was  90%.
Cell cycle analysis
MMCs were collected; resuspended in a solution of 0.1 mg/ml propidium
iodide, 0.2% Tween 20, and 0.2 mg/ml RNase in PBS; incubated in the
dark at 4 C for 2 h; and analyzed by FACS.
Cell culture experiments
6   10
4 freshly isolated MMCs (as described in Cell sorting by flow cy-
tometry) were co-cultured with 6   10
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myotubes in 24 multiwells coated with laminin (Roche). Muscle differentia-
tion was induced using low-serum DM (DME/2% horse serum) for up to 6 d
in the presence or absence of 100 ng/ml human R3–IGF-I (Sigma-Aldrich).
As indicated in Results, in some of the experiments MMCs were cultured in
myoblast GM (50% DME/10% FBS   50% F10/20% FBS/50 ng/ml
FGF) or in bone marrow medium ( MEM/15% FBS supplemented with
IL3, IL6, and stem cell factor cytokines). Cell cultures were then fixed in
1.5% PFA, blocked in blocking buffer, stained for GFP (rabbit; 2  g/ml)
and myogenin (mouse; 0.7  g/ml; BD Biosciences), and incubated with
10  g/ml of the secondary conjugated antibodies anti–rabbit-Alexa488
and anti–mouse-Alexa546. Cell cultures were then washed in PBS and left
in PBS for imaging acquisition. Images of cell cultures were acquired using
a laser-scanning confocal microscope (LSM510; Carl Zeiss MicroImaging,
Inc.) using Plan NeoFluar 20 /0.50 objective lenses and maximum op-
tical section with the LSM software. Background was reduced using
brightness and contrast adjustments, and color balance was performed
to enhance colors. All the modifications were applied to the whole image
using Photoshop 7.0. In these co-culture experiments, myotubes that had
two or more nuclei and were myogenin
  were scored.
Time lapse
6   10
4 freshly isolated MMCs (as described in Cell sorting by flow cy-
tometry) were cultured for 3 d in myoblast GM and then co-cultured with
6   10
4 Ara-C–treated 3-d-old myotubes in 24 multiwells coated with
laminin. Muscle differentiation was induced using low-serum DM. Immedi-
ately after the beginning of the co-culture, cells were monitored using a
time-lapse apparatus (Carl Zeiss MicroImaging, Inc., CO2: CTI-Controller
3700 Digital; temperature: Tempcontrol 37–2 digital; scanning stage:
Incubator XL 100/135 [PECON]) mounted on a laser-scanning confocal
microscope. Images of cell cultures were acquired at 37 C every 10 min
using a Plan NeoFluar 10 /0.50 objective lenses and maximum optical
section with the LSM software. After the acquisition, pictures of the frames
were analyzed using Image Ready 7.0 software.
Online supplemental material
Video 1 shows co-cultures of Ara-C–treated 3-d-old wild-type primary myo-
tubes (GFP
 ) with MMCs (GFP
 ) kept in myoblast GM for 3 d. Online sup-
plemental material is available at http://www.jcb.org/cgi/content/full/
jcb.200506123/DC1.
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